Clinical Trial Update: Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the relative bioavailability of two Moroctocog alfa (AF-CC) formulations in people with Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Moroctocog alfa AF-CC (moroctocog alfa)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 1 | Status: COMPLETED